janus – Page 4 – Communicable Diseases Research

Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation

기계적 환기가 아닌 SARS-Cov-2 감염 환자에서 룩소리티닙의 동정적 사용: 염증 및 환기에 대한 단기 영향

Article

Published on 2021-05-012022-09-11
Journal: Clinical and translational science [Category] SARS, 신약개발,

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

경증 또는 중등도의 COVID-19 폐렴으로 입원한 환자를 위한 염증 신호 억제제(MATIS)의 다군 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-122022-09-10
Journal: Trials [Category] 임상,

[키워드] 24 hours accounted Administered age agreement All participants Allergic reactions approved baseline blind blinded Blinding block Breastfeeding Caregivers cell proliferation childbearing potential clinical clinical outcomes clinically suspected college comparator completion Compliance Concomitant medication Contraception Controlled trial coronavirus COVID-19 COVID-19 disease COVID-19 pneumonia CPAP CRP Data monitoring committee Day death defined Desaturation determine diagnosed disease disease severity dissemination dose drug ECMO effective Efficacy element English enrolment exclusion experimental arm experimental intervention facemask FOS fostamatinib generate GRADE grade 3 Graft graft-versus-host-disease hepatic dysfunction hospital Hospital admission Hospital stay hospitalisation hospitalised patient Hospitalised patients Immune thrombocytopenia Imperial College Healthcare NHS Trust incidence information Informed consent inhibitor Inpatient Inpatients Intervention invasive Invasive mechanical ventilation invasive ventilation investigational agent investigator JAK1 JAK2 janus kinase Kinase inhibitor kinases Laboratory male participants MATIS Mild minimum moderate Moderate COVID-19 moderate to severe Modification multi-arm myelofibrosis nasal oxygen NHS Non-invasive non-invasive ventilation number objective Obstructive obstructive sleep apnoea opinion Ordinal Scale outcome oxygen Pairwise comparison pandemic parallel-group participant Patient Pneumonia polycythaemia vera principal investigator product progression promise proportion protocol random randomisation randomised randomised controlled trial receiving recruit recruited reduce reduce mortality reducing renal impairment renal replacement therapy replacement therapy required Requirement ruxolitinib Sample size sample size calculation Sample size calculations SARS-CoV2 infection scale Secondary objectives selective sequence severe allergic reaction Severe COVID-19 pneumonia severity severity of COVID-19 sexual intercourse signal sleep apnoea Sperm sperm donation spleen Splenomegaly Stage stage 2 Standard Standard of care statistical analysis status Stratification study drug Study protocol supplementary material Symptom systemic inflammation the WHO therapy thrombocytopenia translation Treatment Trial Trial registration Trust tyrosine tyrosine kinase inhibitor Venous Thromboembolism verbal website WHO with COVID-19
[DOI] 10.1186/s13063-021-05190-z PMC 바로가기 [Article Type] Letter

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

Research Article

Published on 2021-01-112022-10-28
Journal: BMC Infectious Diseases [Category] COVID-19,

[키워드] 95% CI Antiviral candidate Clinical outcome conducted controls Coronaviruses COVID-19 COVID-19 patient COVID-19 patients cytokine release discharge disease Efficacy estimate highly pathogenic hospital discharge Human ICU admission indicated infection control interferon interferon treatment investigator janus medRxiv Meta-analysis Mortality non-randomized novel Novel coronavirus pandemic positive Randomized RCT recipient reduced respiratory infection Result risk SARS-CoV-2 searched significantly significantly increased Spread standard treatment supplementary material systematic review therapy These data treated Treatment Treatment outcome trials Type type I interferon viral infection virus while
[DOI] 10.1186/s12879-020-05730-z PMC 바로가기 [Article Type] Research Article

COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm

Oncology

Published on 2021-01-082022-10-31
Journal: Frontiers in Oncology [Category] COVID-19,

[키워드] Activation admitted to ICU approach approved CAR-T caused COVID-19 COVID-19 mortality COVID-19 patient CRS cytokine cytokine release deleterious effect dendritic cells evaluated events ferritin fibrosis graft-versus-host-disease hematologic hematological high mortality HLH Hospitalization hyperinflammation ICU IL-6 immune-cell Immunotherapy impacted IMPROVE Italy Jak JAK1 JAK2 janus kinase limit lymphocyte Macrophage management Migration molecular molecular mechanism multi-organ failure myelofibrosis outbreak outcome overcome pathogenic Patient Proinflammatory cytokine reducing Respiratory failure ruxolitinib SARS-CoV-2 selective Signaling solid tumor storm syndrome tissue damage TNFα treated Treatment turn virus
[DOI] 10.3389/fonc.2020.599502 PMC 바로가기 [Article Type] Oncology

Ruxolitinib for Severe COVID-19-Related Hyperinflammation in Nonresponders to Steroids

스테로이드에 반응하지 않는 환자의 중증 COVID-19 관련 과염증에 대한 룩소리티닙

Article

Published on 2021-01-012022-09-12
Journal: Acta haematologica [Category] 진단,

[키워드] acute respiratory syndrome appear Chilean clinical condition clinical evolution Complete consecutive patient coronavirus Coronavirus disease-19 COVID-19 demonstrated develop discharge effective strategy Evolution hyperinflammation hyperinflammatory state Infection Inflammation JAK inhibitor janus Janus kinase/signal transducer and activator of transcription less lung lesions management mild infection nasal Nonresponder outcomes PaFi Patient patients presenting Prospective Study public health Randomized controlled trial reduced required resolved Respiratory failure ruxolitinib SARS-CoV-2 severe disease severe respiratory failure severe SARS-CoV-2 steroid Steroids subsequent therapy Tocilizumab tocilizumab therapy treated Treatment viral-induced was performed
[DOI] 10.1159/000516464 PMC 바로가기 [Article Type] Article

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

JAK 억제는 SARS-CoV-2 간 감염성을 감소시키고 염증 반응을 조절하여 이환율 및 사망률을 감소시킵니다

Observational Study

Published on 2021-01-012022-09-11
Journal: Science Advances [Category] 신약개발, 임상, 진단, 치료제,

[키워드] 95% CI ACE2 expression adverse events Antiviral antivirals Baricitinib benefit Cell cells Cohort controlled trials Culture cytokine Cytokine storm Efficacy elderly patients greater host protein host proteins human liver increase Inflammatory response inhibited inhibitor interferon Jak janus Janus kinase kinases liver liver cells median age Microscopy moderate-severe modulate morbidity and mortality Mortality outcome parenchymal parenchymal cells Patient platelet activation Pneumonia Randomized controlled trials reduce Replication reveal RNA-Seq SARS-CoV-2 SARS-CoV-2 pneumonia the cytokine storm Viral viral entry viral load quantification
[DOI] 10.1126/sciadv.abe4724 PMC 바로가기 [Article Type] Observational Study

JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations

Review Articles

Published on 2020-10-152022-11-01
Journal: Cardiovascular Endocrinology & Metabolism [Category] COVID-19,

“Small” Intestinal Immunopathology Plays a “Big” Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor

Immunology

Published on 2020-06-262022-10-31
Journal: Frontiers in Immunology [Category] COVID-19, MERS,

[키워드] accompanied administration affected antibodies Antigen blood pressure bowel caused characterized contribute contributed coronavirus disease COVID-19 CRS cytokine cytokine production Cytokine release syndrome deficiency Degradation down-regulated expression Extracellular matrix HLA class II transgenic mice HLA-DR3 IFN-γ IL-17A immune Immunopathogenesis immunopathology indicated inflammatory pathway inhibitor inhibitors intestinal intestinal tissue JAK inhibitor janus kinase lethal maintain mice Mortality multiple organ multiple organ dysfucntion multiple organ dysfunction organ organ function pathogenic pathology pathway pro-apoptotic receptor Release RNA sequencing role SARS-CoV-2 selective severity signaling pathway significantly significantly increased specific treatment staphylococcal superantigens Support systemic level T cell T cell activation therapy Toxic shock syndrome transgenic mice Treatment TSS
[DOI] 10.3389/fimmu.2020.01311 PMC 바로가기 [Article Type] Immunology

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

Article

Published on 2020-06-092022-10-04
Journal: Leukemia [Category] SARS, 임상, 치료법, 치료제,

COVID-19 vaccine design: the Janus face of immune enhancement

COVID-19 백신 디자인: 면역 강화의 야누스 얼굴

Article

Published on 2020-06-012022-09-11
Journal: Nature reviews. Immunology [Category] Fulltext, SARS, 비임상,